Is BVXV or NOBL a better dividend investment in 2026?

BVXV currently yields 147.06% with a 5% 5-year dividend growth rate. NOBL yields 2.17% with 5% growth. The better choice depends on your goal: BVXV offers higher current income.

What is the dividend yield difference between BVXV and NOBL?

BVXV has a forward dividend yield of 147.06% ($2.00/share annually). NOBL yields 2.17% ($2.27/share annually). The yield gap is 144.89 percentage points.

Home › Compare › BVXV vs NOBL

BVXV vs NOBL: Dividend Comparison 2026

BVXV yields 147.06% · NOBL yields 2.17%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 BVXV wins by $22.58M in total portfolio value

INVESTMENT

TIME HORIZON10 years

BVXV

● Live price

147.06%

Share price

$1.36

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.60M

Annual income

$9,667,205.19

Full BVXV calculator →

NOBL

● Live price

2.17%

Share price

$104.67

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.9K

Annual income

$249.78

Full NOBL calculator →

Portfolio growth — BVXV vs NOBL

📍 BVXV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BVXV	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BVXV + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BVXV pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BVXV

Annual income on $10K today (after 15% tax)

$12,500.00/yr

After 10yr DRIP, annual income (after tax)

$8,217,124.41/yr

NOBL

Annual income on $10K today (after 15% tax)

$184.52/yr

After 10yr DRIP, annual income (after tax)

$212.31/yr

At 15% tax rate, BVXV beats the other by $8,216,912.10/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BVXV + NOBL for your $10,000?

BVXV: 50%NOBL: 50%

100% NOBL50/50100% BVXV

Portfolio after 10yr

$11.31M

Annual income

$4,833,727.48/yr

Blended yield

42.74%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BVXV buys

NOBL buys

No recent congressional trades found for BVXV or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBVXVNOBL

Forward yield	147.06% ✓	2.17%
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$22.60M	$22.9K ✓
Annual income after 10y	$9,667,205.19 ✓	$249.78
Total dividends collected	$20.88M ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: BVXV vs NOBL ($10,000, DRIP)

Year	BVXV Portfolio	BVXV Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$25,406	$14,705.88	$10,917	$217.08	+$14.5K → BVXV
2	$62,102	$34,917.38	$11,903	$221.48	+$50.2K → BVXV
3	$146,216	$79,767.65	$12,962	$225.68	+$133.3K → BVXV
4	$331,975	$175,523.78	$14,099	$229.68	+$317.9K → BVXV
5	$727,658	$372,444.73	$15,319	$233.49	+$712.3K → BVXV
6	$1,541,551	$762,956.42	$16,628	$237.10	+$1.52M → BVXV
7	$3,160,048	$1,510,588.88	$18,033	$240.53	+$3.14M → BVXV
8	$6,275,251	$2,893,998.93	$19,539	$243.78	+$6.26M → BVXV
9	$12,085,478	$5,370,960.29	$21,154	$246.86	+$12.06M → BVXV
10	$22,598,667	$9,667,205.19	$22,884	$249.78	+$22.58M → BVXV

BVXV vs NOBL: Complete Analysis 2026

BVXV — Stock

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Full BVXV Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this BVXV vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BVXV vs SCHD BVXV vs JEPI BVXV vs O BVXV vs KO BVXV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.